Immunotherapy and Viral Oncology in Cancer Treatment: A Survey

www.surveyx.cn

Abstract

This survey paper explores the multidisciplinary field of immunotherapy, viral oncology, and cancer treatment, emphasizing the integration of immunology, virology, and oncology to advance therapeutic strategies. It highlights the pivotal role of immune checkpoint inhibitors, CAR T-cell therapy, and oncolytic virotherapy in enhancing cancer treatment efficacy. The paper examines the development of vaccines targeting oncogenic viruses, such as HPV, and discusses innovative approaches, including trained immunity and deep learning technologies, to improve vaccine efficacy. It underscores the significance of understanding immune system dynamics and tumor microenvironment interactions, which influence treatment outcomes and resistance mechanisms. The paper also addresses the challenges of treatment efficacy, resistance, and safety concerns, emphasizing the need for personalized medicine and predictive biomarkers to optimize therapeutic interventions. Technological advancements in nanomedicine, mathematical modeling, and integrated therapeutic strategies are highlighted as transformative tools in the field. The survey concludes by underscoring the importance of a multidisciplinary approach in advancing cancer treatment through immunotherapy and viral oncology, with significant potential for future breakthroughs. Ongoing research is essential to refine models, enhance biomarker development, and explore novel therapeutic combinations to improve patient outcomes and address the complexities of virus-induced cancers.

1 Introduction

1.1 Multidisciplinary Nature of the Field

The field of immunotherapy and viral oncology exemplifies a multidisciplinary approach, integrating diverse scientific domains to enhance cancer treatment strategies. The Kirschner-Panetta model illustrates the intersection of mathematics and biology in modeling cancer immunotherapy dynamics [1]. Advances in AI-ready multiplex staining datasets provide standardized benchmarks, reducing interobserver variability and enhancing pathology applications [2]. Additionally, the concept of liquid metal-enabled electrobiology introduces innovative electrotherapy strategies, reflecting the synergy between engineering and biological sciences [3].

Cytokine research in clinical cancer immunotherapy underscores the contributions from immunology and oncology, driving therapeutic advancements [4]. The co-evolution of viruses and adaptive immune systems highlights the interdisciplinary nature of virology and immunology, emphasizing immune system dynamics in viral oncology [5]. Furthermore, antibody interactions during viral infections, particularly in dengue, illustrate the complex interplay between immunology and virology, where antibodies can neutralize or enhance viral activity [6].

A comprehensive perspective on oncology, encompassing historical context, diagnostic methods, and treatment strategies, is essential for understanding the multifaceted nature of cancer research [7]. The interplay between immunology, oncology, and pharmacology is crucial in developing



Figure 1: chapter structure

combination strategies for immunotherapy [8]. Mathematical and computational modeling further addresses challenges in designing effective cancer immunotherapies, highlighting the importance of interdisciplinary collaboration [9].

The interaction between electromagnetic fields and ion channels, particularly in immune responses, illustrates the interdisciplinary aspects of immunotherapy and viral oncology [10]. Challenges in quantifying lymphocytes in histopathology slides necessitate the integration of immunotherapy and histopathological techniques [11]. These examples underscore the dynamic interplay of various scientific domains in advancing innovative cancer therapies, emphasizing the importance of interdisciplinary collaboration in addressing the complexities of viral oncology and immunotherapy.

1.2 Significance of Immune System Understanding

Understanding the immune system's response to oncogenic viruses is pivotal in advancing cancer treatment, particularly for aggressive cancers like triple-negative breast cancer (TNBC), which have limited targeted therapeutic options and poor prognoses [12]. The complexity of immune responses in the tumor microenvironment necessitates a comprehensive classification and understanding of immune cells, essential for optimizing immunotherapeutic strategies and improving patient outcomes [13].

Integrating immunotherapy with dietary interventions, such as the ketogenic diet, underscores the multifaceted approach needed to enhance treatment efficacy in breast cancer, highlighting the importance of understanding immune system dynamics and their interaction with oncogenic viruses [14]. The innate immune response also plays a critical role in viral infections, as evidenced by the

development of effective vaccines against viruses like COVID-19, illustrating the broader implications of immune system understanding beyond cancer [15].

Glycosylation processes are crucial for the efficacy and safety of immunotherapeutics, influencing the immune system's ability to recognize and respond to cancer cells [16]. The intricate oscillations and interactions between cancer cells and immune cells necessitate realistic modeling to accurately capture dynamics, vital for developing effective cancer therapies [17].

In metastatic breast cancer, the limited effectiveness of current treatments highlights the potential of immunotherapy to improve outcomes, reinforcing the importance of a deep understanding of immune system responses to oncogenic viruses in cancer treatment [18]. Collectively, these insights underscore the necessity of advancing our understanding of the immune system to develop innovative cancer treatments and improve prognoses for patients facing virus-induced cancers.

1.3 Development of Vaccines

The development of vaccines targeting oncogenic viruses represents a crucial advancement in cancer prevention strategies. Human Papillomavirus (HPV) vaccines have been pivotal in preventing virus-induced cancers such as cervical cancer, showcasing the importance of antibody training to recognize and neutralize specific viral antigens [19]. These vaccines exemplify how targeted immunological interventions can mitigate cancer risk by preemptively addressing viral oncogenesis.

Moreover, integrating personalized nano-immunotherapy strategies into vaccine development aims to enhance treatment outcomes by tailoring interventions to individual patient profiles [20]. This approach not only improves vaccine efficacy but also aligns with the broader trend towards personalized medicine, optimizing therapeutic interventions based on genetic, immunological, and environmental factors unique to each patient.

Ongoing research and innovation in vaccine development underscore the potential of these interventions to significantly reduce cancer incidence linked to viral infections. By harnessing advancements in immunology and nanotechnology, researchers are developing innovative and personalized vaccine strategies that effectively combat the multifaceted challenges posed by oncogenic viruses. These strategies aim to enhance the immune response against cancer cells while addressing the limitations of current immunotherapies, such as adverse effects and variable efficacy. Integrating nanomedicine approaches, which improve the delivery and targeting of therapeutic agents, holds the potential to optimize treatment outcomes for a broader range of patients [21, 22, 23, 24, 25].

1.4 Structure of the Survey

This survey provides a comprehensive examination of the intersection between immunotherapy, viral oncology, and cancer treatment. The initial section introduces the multidisciplinary nature of the field, emphasizing the integration of diverse scientific domains such as immunology, virology, and oncology. Following this, the significance of understanding the immune system's response to oncogenic viruses is explored, highlighting its critical role in advancing cancer treatment strategies. The development of vaccines targeting oncogenic viruses is then discussed, showcasing their importance in cancer prevention.

The background section offers an overview of the relationship between viruses and cancer, detailing the historical context and evolution of immunotherapy and viral oncology. Key definitions and core concepts are presented to establish a foundational understanding, including mechanisms of viral-induced cancer and the immune system's dynamics in combating oncogenic viruses.

Subsequent sections delve into the role of oncogenic viruses in cancer, examining specific examples, their mechanisms of action, and their epidemiological impact on global cancer incidence. Various immunotherapy strategies in viral oncology are explored, including immune checkpoint inhibitors, CAR T-cell therapy, and oncolytic virotherapy, focusing on mechanisms, efficacy, and challenges.

The survey further investigates vaccine development for virus-induced cancers, evaluating current strategies and effectiveness while highlighting innovative approaches and the role of predictive biomarkers in personalized vaccines. The interactions between tumor virology and the immune response are critically examined to identify innovative therapeutic strategies, particularly how oncolytic virotherapy can be enhanced by reprogramming the immune microenvironment. This includes

analyzing the dynamics of viral infectivity, the role of cytotoxic T cells in tumor cell apoptosis, and the impact of immune checkpoint inhibitors, essential for overcoming resistance to treatment and improving clinical outcomes [25, 26, 27, 28].

Finally, the survey addresses current challenges and future directions in the field, such as treatment efficacy, resistance, side effects, and safety concerns, alongside potential technological advancements and innovations in personalized medicine and biomarker development. The conclusion synthesizes key findings from recent advancements in cancer treatment, emphasizing the critical role of a multidisciplinary approach that integrates immunotherapy and viral oncology. It highlights the need for combination strategies—pairing immunotherapy with chemotherapy, radiation, and targeted therapies—to overcome resistance and enhance treatment efficacy. Additionally, the conclusion points to promising avenues for future breakthroughs, including the development of advanced drug delivery systems and innovative therapies that harness the immune system's natural mechanisms to combat cancer, thereby improving patient outcomes [23, 25].The following sections are organized as shown in Figure 1.

2 Background

2.1 Viruses and Cancer: An Overview

The intricate relationship between viruses and cancer is pivotal to understanding tumorigenesis, with oncogenic viruses like Epstein-Barr virus (EBV) and Human Papillomavirus (HPV) playing significant roles. EBV, prevalent in the human population, is linked to nasopharyngeal carcinoma and certain lymphomas [29]. HPV is closely associated with cervical cancer, as exemplified by the high incidence rates in Moldova due to inadequate screening and vaccination efforts [30]. These viruses promote cancer through mechanisms such as integrating viral DNA into host genomes and disrupting cellular pathways, often leading to chronic inflammation and immune evasion [5].

The detection of viral DNA in tumors is crucial for understanding viral oncogenesis, with advanced methods like the XVir deep learning architecture enhancing detection accuracy [31]. However, challenges remain in identifying viral sequences from metagenomic data, especially for short or unknown sequences [32]. Accurate classification of immune cell subtypes is also essential for comprehending immune interactions in cancer [13].

Oncolytic virotherapy, which exploits viruses to selectively infect and destroy cancer cells, offers promising therapeutic potential [26]. Yet, the limited effectiveness of current immunotherapies, especially for non-immunoresponsive tumors, necessitates further exploration and innovation [20]. Approximately 15% of cancers worldwide are associated with viral infections, including HPV, hepatitis B and C, EBV, and HIV. The potential of oncolytic virotherapy is hindered by oscillatory responses within tumor and virus populations, highlighting the need for integrated therapeutic strategies [27].

2.2 Oncogenic Viruses and Tumor Development

Oncogenic viruses are integral to the development and progression of various cancers. EBV's transition between latency phases affects its oncogenic potential and is crucial for understanding associated malignancies [29]. HPV's role in cervical cancer is particularly evident in regions with high incidence rates, such as Moldova, where public health measures are needed to address HPV-related cancers [30].

Oncolytic viruses show promise by selectively lysing cancer cells and stimulating anti-tumor immune responses [33]. However, challenges such as effective treatments for p53-deficient tumors remain [26]. Understanding virus-human protein interactions is essential for developing targeted antiviral therapies, although accurate prediction is complicated by the dynamic nature of these interactions and limited training data [34].

Glioblastoma multiforme, an aggressive brain tumor, exemplifies the challenges posed by immune suppression, necessitating a deeper understanding of viral contributions to tumor progression [35]. The detection of viral DNA in tumors is hindered by the high divergence of oncoviral families, emphasizing the need for advanced molecular techniques [31]. Addressing the complexities of virus-induced cancers involves innovative therapeutic strategies like oncolytic virotherapy and precision

medicine, which are essential for combating tumor resistance and improving patient outcomes [26, 27].

2.3 Historical Context of Immunotherapy

The evolution of immunotherapy in oncology has been marked by significant milestones, overcoming early challenges posed by tumor microenvironments and cancer cell heterogeneity [9]. Advances over the past three decades have transformed immunotherapy into a cornerstone of cancer treatment, driven by a deeper understanding of immune mechanisms and novel approaches like immune checkpoint inhibitors and adoptive cell therapies [16, 25].

Combination therapies have emerged as pivotal, with FDA approvals for several synergistic combinations enhancing therapeutic efficacy [8]. Adaptive enrichment designs in clinical trials have facilitated personalized treatment approaches, tailoring therapies to individual molecular and genetic profiles [36]. Despite these advancements, challenges such as therapy-related toxicities and tumor microenvironment complexities persist, necessitating ongoing research and the integration of biomarkers into treatment design [37].

The historical trajectory of immunotherapy reflects continual refinement and integration of innovative technologies, enhancing the precision and effectiveness of cancer treatment. As oncology advances, it holds the potential to transform cancer care through precision medicine and immunotherapy, offering hope for patients with complex malignancies [38, 22, 23].

2.4 Evolution of Viral Oncology

Viral oncology has evolved through significant research advancements in understanding virus-cancer interactions. Mathematical models have been instrumental in analyzing viral infectivity dynamics in oncolytic virotherapy, enhancing treatment efficacy by integrating virotherapy with chemotherapy [39]. Innovations like the XVir deep learning architecture have improved viral DNA detection in cancer samples, highlighting the role of viral infections in approximately 15% of cancers globally [31].

Research on spatial dynamics in viral oncology has elucidated virus-host tissue interactions, influencing tumor progression and treatment outcomes [40]. Understanding immune evasion mechanisms and the efficacy of immunotherapeutic agents, particularly in hepatocellular carcinoma, reflects ongoing efforts to overcome immune resistance in virus-induced cancers [41].

Mathematical modeling has emerged as a powerful tool, providing insights into virus-immune dynamics and informing vaccine and immunotherapy development [42]. Advanced methods like DeepVirFinder enhance viral sequence prediction in metagenomic data, deepening our understanding of viral taxonomy [32]. Bayesian Nonparametric Meta-Analysis (BNPMA) methods allow for flexible modeling of complex data correlations, enhancing therapeutic precision in viral oncology [37].

New mathematical models incorporating competitive and synergistic antibody binding to viral receptors improve immune response predictions and optimize therapeutic strategies [6]. Despite challenges in identifying patient subgroups for treatment, the ongoing evolution of viral oncology, driven by interdisciplinary research and technological advancements, promises to revolutionize cancer treatment and provide hope for patients with complex malignancies.

In recent years, the field of immunotherapy has undergone significant transformation, driven by advances in our understanding of the interactions between viral oncology and immune responses. To elucidate this complex relationship, Figure 2 presents a detailed illustration of the hierarchical structure of core concepts in immunotherapy and viral oncology. This figure categorizes key terminologies and mechanisms associated with viral-induced cancer, while also emphasizing the dynamics of the immune system. Notably, it highlights the integration of innovative approaches, the role of viral integration and immune response, as well as the challenges and advancements within immune system dynamics. By visually representing these interconnections, the figure enhances our understanding of the multifaceted nature of immunotherapy and its implications for cancer treatment.



Figure 2: This figure illustrates the hierarchical structure of core concepts in immunotherapy and viral oncology, categorizing key terminologies, mechanisms of viral-induced cancer, and immune system dynamics. It highlights the integration of innovative approaches, the role of viral integration and immune response, and the challenges and advancements in immune system dynamics.

3 Definitions and Core Concepts

3.1 Key Terminologies in Immunotherapy and Viral Oncology

A comprehensive understanding of immunotherapy and viral oncology involves several foundational concepts. Human Papillomavirus (HPV) exemplifies the connection between oncogenic viruses and cancer, particularly cervical cancer [30]. Integrating nanomedicine into immunotherapy marks a transformative shift, enabling personalized and targeted treatment approaches [20]. Deep learning and molecular tumor biomarkers are crucial for predictive analytics and personalized medicine, enhancing the analysis of hematoxylin and eosin (HE) stained images for tumor characterization [43]. Glycosylation, a critical factor in immunotherapeutics, significantly influences their efficacy and safety, highlighting the importance of biochemical modifications in therapeutic development [16].

The survey also explores human immunology, focusing on immune cell subsets and immune-mediated diseases, which are vital for optimizing immunotherapies [21]. Liquid Metal Enabled Electrobiology (LME) introduces novel methods for delivering electrical stimulation to biological tissues, merging engineering with biology to enhance therapeutic strategies [3]. These terminologies provide a framework for understanding the complex dynamics and advanced strategies in immunotherapy and viral oncology, including immune checkpoint inhibitors, adoptive cell therapy, combination therapies, and advanced delivery technologies, essential for overcoming treatment resistance and improving therapeutic efficacy [21, 23, 44, 8, 25].

3.2 Mechanisms of Viral-Induced Cancer

Viral oncogenesis involves a complex interplay of viral integration, immune dynamics, and tumor microenvironment interactions. Viral genetic material integration into the host genome disrupts cellular regulatory pathways, facilitating oncogenesis. Advanced genomic tools, like the XVir pipeline, enhance our ability to identify viral sequences in human tumor data, elucidating viral contributions to cancer development [31]. Mathematical modeling is crucial for understanding viral-induced cancer dynamics. Ordinary differential equations simulate interactions among tumor cells, immune cells, and therapeutic interventions, providing insights for optimizing treatment strategies [42]. Spatially explicit stochastic models capture intra-tumor heterogeneity and its effects on immune responses, offering detailed views of spatial interactions between CD8+ T cells and tumor cells [45].

The immune response to viral oncogenesis is initiated by pattern recognition receptors (PRRs) in the innate immune system, which detect viral antigens [15]. The competition and oscillations between immune and cancer cells underscore the significance of spatial dynamics and environmental

heterogeneity in shaping immune responses to viral infections [17]. Identifying neoantigens from mass spectrometry data is vital for developing personalized cancer vaccines targeting virus-induced tumors, representing novel immunotherapy targets [46]. The tumor microenvironment (TME) significantly influences viral-induced cancer progression and immune evasion of virus-infected tumor cells. Detecting lymphocytes within the TME is essential for understanding the immune landscape and its effects on tumor progression [11].

As depicted in Figure 3, this figure illustrates the hierarchical structure of mechanisms involved in viral-induced cancer, emphasizing the roles of viral integration, immune response, and tumor microenvironment. Each category explores specific aspects, such as genomic disruptions, immune dynamics, and microenvironmental influences, highlighting their contributions to cancer development and progression. The bifurcation diagram maps antigen presentation dynamics, reflecting varying efficacy levels, while the comparative graph evaluates successful versus unsuccessful treatments, emphasizing therapy's impact on outcomes. Together, these visuals underscore the complexity of viral-induced cancer mechanisms and the critical role of biological processes and therapeutic strategies in managing this disease [47, 26].



Figure 3: This figure illustrates the hierarchical structure of mechanisms involved in viral-induced cancer, emphasizing the roles of viral integration, immune response, and tumor microenvironment. Each category explores specific aspects, such as genomic disruptions, immune dynamics, and microenvironmental influences, highlighting their contributions to cancer development and progression.

3.3 Immune System Dynamics in Combating Oncogenic Viruses

The immune response to oncogenic viruses employs a sophisticated array of cellular and molecular mechanisms to identify and eliminate virus-infected cells, thus reducing cancer risk. Cytotoxic T lymphocytes (CTLs) are central to this defense, targeting specific viral epitopes, especially in rapidly mutating infections like HIV, where the immune system must adapt to evolving strains [48]. The spatial organization of immune cells within the tumor microenvironment significantly influences their ability to engage with malignant cells, highlighting the importance of spatial dynamics in immune efficacy [49]. Tools like ALICE facilitate the detection of T cell receptors (TCRs) recognizing specific antigens, enhancing our understanding of immune responses in oncogenic contexts [50].

The 'predator-predator' model illustrates the dynamic interactions between the immune system and viral mutations, underscoring the need for an adaptable immune surveillance system responsive to the changing landscape of viral antigens [51]. This adaptability is supported by the immune system's capacity to distinguish and remember self-antigens, allowing effective responses to nonself antigens through T cell regulatory mechanisms [52]. Radiological biomarkers correlated with immune-related genetic markers represent significant advancements in understanding immune responses, particularly in glioblastoma treatment, laying the groundwork for integrating immune dynamics into therapeutic strategies [53]. Additionally, enhancing Kv1.3 potassium conductance through ELF-EMF exposure presents potential strategies against oncogenic influences [10].

Despite these advancements, challenges such as tumor immunosuppression and the complexity of immune responses can hinder treatment outcomes [9]. Combination therapies aiming to leverage the synergistic effects of multiple modalities are being explored to enhance treatment efficacy [25]. The effectiveness of immune responses is also influenced by tumor heterogeneity, particularly the diversity of cancer cell sub-populations and the proportion of immunogenic cells [45]. Understanding

immune dynamics in combating oncogenic viruses is essential for developing innovative cancer prevention strategies and improving patient outcomes.

4 Role of Oncogenic Viruses in Cancer

4.1 Role of Viral Diversity and Oncogenic Mechanisms

Oncogenic viruses exhibit diverse mechanisms that significantly contribute to cancer development, with each virus uniquely interacting with host cellular systems. The tumor microenvironment (TME)'s immune cell heterogeneity is crucial in tumor progression due to intricate engagements with viral components [40, 49]. This spatial distribution acts as a predictive biomarker for cancer recurrence, highlighting the importance of understanding TME dynamics. Human Papillomavirus (HPV) serves as a prime example of an oncogenic virus with well-documented infection dynamics and oncogenic potential [54]. Regulatory mechanisms of viral gene expression, including steric effects and cooperative interactions, are essential for understanding HPV's role in oncogenesis [29]. These interactions between viral genes and host processes can lead to malignant transformations, underscoring the complexity of viral oncogenesis.

Optimal control theory provides insights into virus propagation, analyzing temporal dynamics of viral infections and their implications for tumor progression [55]. Molecular MRI techniques elucidate biological processes linked to tumor responses, shedding light on viral contributions to cancer development [56]. Recent findings on Kv1.3 potassium channels, modulated by extremely low-frequency electromagnetic fields (ELF-EMF), reveal novel oncogenic mechanisms, given their integral role in immune cell function and cancer progression [10]. Multiscale modeling approaches have enhanced understanding of tumor-ECM-OV dynamics, encompassing cell-cell and cell-matrix interactions [57]. Tumors with higher intratumor heterogeneity (ITH) evade immune detection more effectively, resulting in poorer immunotherapy outcomes [45], emphasizing the need for tailored immunotherapeutic strategies.

Research into viral diversity and oncogenic mechanisms is advancing rapidly, supported by theoretical frameworks and clinical methodologies. Approximately 15% of global cancers are attributed to viral infections, including HPV, hepatitis B and C, Epstein-Barr virus, and human immunodeficiency virus. Sequencing technology advancements enable large-scale tumor DNA analyses, exploring connections between viral pathogens and various cancers. However, the diversity among oncoviral families complicates accurate viral DNA detection, critical for such analyses. Tools like XVir, a transformer-based deep learning architecture, enhance viral DNA identification in human tumors, offering superior detection accuracy and efficiency [31]. Mathematical models examining viral infectivity dynamics in oncolytic virotherapy reveal complexities in viral-tumor interactions, suggesting that enhancing viral infectivity may improve treatment outcomes, but complete tumor eradication requires complementary therapeutic strategies [27]. By elucidating intricate interactions between viruses and host cells, researchers can develop more effective strategies for preventing and treating virus-induced cancers.

Figure 4 illustrates the complexity and diversity of oncogenic viruses in cancer through two visual aids. The first image analyzes various image segmentation techniques applied to histological images of lung tissue stained with hematoxylin and eosin, crucial for understanding how segmentation approaches influence cancer research. The second image outlines key computational challenges in human virome studies, such as accurately identifying viruses and improving virus genome assembly. These images emphasize the intricate interplay between viral diversity, oncogenic mechanisms, and computational efforts required to advance understanding [26, 58].

4.2 Epidemiology and Global Impact

Oncogenic viruses significantly influence global cancer incidence, with Human Papillomavirus (HPV) being extensively studied for its substantial contribution to cervical cancer worldwide. The high prevalence of HPV-related cancers in regions with limited vaccination and screening, such as Eastern Europe, underscores the need for comprehensive public health strategies [30]. Hepatitis B and C viruses (HBV and HCV) are major contributors to global cancer incidence, particularly hepatocellular carcinoma (HCC). Their transmission dynamics, often linked to healthcare practices and blood transfusions, necessitate effective infection control measures and vaccination programs [29]. The



(a) Comparison of Different Image Segmentation Techniques[26]



(b) Computational challenges in human virome studies[58]

Figure 4: Examples of Role of Viral Diversity and Oncogenic Mechanisms

co-evolution of these viruses with human populations has led to diverse viral genotypes with unique oncogenic potentials, complicating global control efforts [5].

The Epstein-Barr Virus (EBV), associated with nasopharyngeal carcinoma and certain lymphomas, shows varied geographical distribution, with higher incidences in Southeast Asia and Africa [29]. This variation, influenced by genetic, environmental, and cultural factors, necessitates tailored interventions for affected populations. Oncolytic virotherapy, using viruses to target and destroy cancer cells, offers a promising strategy against the global cancer burden. However, its efficacy is influenced by the genetic and environmental diversity of viral strains, necessitating personalized treatment approaches [33].

The global impact of oncogenic viruses on cancer incidence is further complicated by challenges in accurately identifying viral sequences within tumors. Advanced molecular techniques, such as the XVir pipeline, are crucial for enhancing understanding of viral contributions to cancer and developing targeted interventions [31]. The epidemiological impact of oncogenic viruses on global cancer rates necessitates coordinated international efforts to improve surveillance, vaccination, and treatment strategies. By addressing multifaceted challenges posed by various oncogenic viruses, including HPV, HBV, HCV, and EBV, the global health community can enhance prevention strategies, improve early detection methods, and advance treatment options, ultimately striving to reduce the incidence of virus-induced cancers and alleviate the overall cancer burden worldwide [31, 58, 26, 7].

5 Immunotherapy Strategies in Viral Oncology

5.1 Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have transformed the management of virus-induced cancers by targeting immune checkpoints such as PD-1 and PD-L1, which are exploited by tumor cells to evade immune detection. These inhibitors enhance survival outcomes by disrupting inhibitory signals that prevent T cell activation, thus promoting the recognition and destruction of tumor cells, especially in malignancies where viral proteins aid immune evasion [23, 34]. Mathematical models of tumor-immune interactions provide insights into the phases of immunoediting—elimination, equilibrium, and escape—suggesting that ICIs can significantly alter tumor progression by modulating immune dynamics [59]. Additionally, studies on antibody-virus interactions, particularly with HPV, emphasize the role of antibody distribution and binding efficiency in optimizing ICI therapies [19]. Despite their potential, ICIs encounter challenges such as T cell exhaustion due to prolonged antigen exposure, leading to reduced functionality [13]. Addressing these involves exploring combination therapies and strategies to rejuvenate T cell responses. Advanced computational models predicting virus-human

protein interactions can refine ICI applications by deepening the understanding of viral oncogenesis and immune dynamics [34].

5.2 CAR T-Cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a revolutionary treatment, particularly for hematological malignancies like B-cell acute lymphoblastic leukemia (ALL), demonstrating substantial clinical success. This approach involves engineering T cells to express receptors that specifically target tumor antigens, facilitating their recognition and destruction [60, 61]. Its application in viral oncology is promising, with potential for treating virus-induced cancers. Mathematical models of CAR T-cell dynamics provide insights into optimal activation conditions and factors influencing therapeutic outcomes [60]. Beyond hematological cancers, CAR T-cell therapy is being explored for solid tumors, including lung cancer, where clinical trials indicate potential for adoptive cell therapies [62]. However, challenges in translating this approach to solid tumors, often due to hostile microenvironments, are highlighted in systematic reviews [63]. Understanding B-cell dynamics is crucial for sustaining CAR T-cell activation and achieving long-term success. Enhancing efficacy involves addressing resistance mechanisms [64]. Research into integrating CAR T-cell therapy with other treatments, such as pembrolizumab and chemotherapy in triple-negative breast cancer (TNBC), aims to improve immune cell infiltration and outcomes [12].

5.3 Oncolytic Virotherapy

Oncolytic virotherapy leverages viruses that selectively infect and lyse cancer cells, sparing healthy cells, thereby offering a promising strategy for targeting virus-induced cancers [65]. This method induces direct tumor cell lysis and stimulates a systemic anti-tumor immune response, enhancing therapeutic outcomes [28]. Integrating oncolytic viruses with existing therapies, such as chemotherapy, has shown potential to optimize efficacy, as supported by mathematical models exploring synergistic effects [39]. Understanding the spatial dynamics of viral spread within tumors is crucial for evaluating oncolytic virotherapy's effectiveness. The multicellular tumor-immune-virus (TIV) model illustrates how spatial discretization affects infection rates and outcomes [66]. Hybrid modeling approaches combining stochastic agent-based models with continuum frameworks provide a comprehensive view of interactions between cancer cells, oncolytic viruses, and the tumor microenvironment [67]. Despite its promise, oncolytic virotherapy faces challenges such as efficient viral delivery and host immune responses, which can limit viral replication and spread [27]. Studies on viral infectivity and immune response interplay elucidate their roles in modulating efficacy [27]. Engineering oncolytic virus strains, like the Newcastle disease virus, shows potential for designing viruses with enhanced properties tailored for specific cancers [68]. The interaction between oncolytic viruses and the heterogeneous extracellular matrix (ECM) significantly influences virotherapy success. A two-scale moving boundary approach simulates these interactions, shedding light on the ECM's role in modulating viral spread and efficacy [57]. Combining oncolytic virotherapy with TCR T cell therapy and IL-2 treatment, as indicated in mathematical models, illustrates the potential for improving outcomes by targeting both tumor cells and the immune response [69].

5.4 Combination Therapy Approaches

Combination therapy approaches are increasingly favored in cancer treatment, particularly for virus-induced malignancies, by harnessing the synergistic effects of multiple modalities to enhance efficacy and address resistance. Integrating immunotherapy with chemotherapy, radiation therapy, and novel therapies has been a primary research focus, with several FDA-approved combinations improving patient outcomes [25]. These strategies address various aspects of the tumor microenvironment, thereby enhancing treatment efficacy. Mathematical modeling is pivotal in optimizing combination therapies, offering insights into treatment interaction dynamics. Models incorporating B-cell dynamics provide a deeper understanding of CAR T-cell therapy, suggesting pharmacological interventions to boost B-cell production and improve outcomes [64]. Furthermore, integrating time delays and non-local infection terms in oncolytic virus therapy models enhances efficacy by capturing intricate treatment dynamics [65]. The necessity for combination strategies is underscored in cytokine therapy, where enhancing current approaches through combinations can improve efficacy [70]. A proposed data-centric optimization pipeline enhances lymphocyte detection performance, representing a novel approach to improving immunotherapy strategies via optimized immune cell interactions [11]. Understanding

the complex interplay between tumor heterogeneity and immune response is critical, as variations in antigen presentation can significantly influence immune surveillance and treatment outcomes [45]. Future research should prioritize developing novel delivery systems to enhance immunotherapy targeting in solid tumors and exploring combination therapies that can improve overall efficacy [23]. The potential of combination therapies is further supported by adaptive strategies, such as the Adaptive Enrichment Design (AED), which facilitates adaptive selection of patient populations based on interim analysis results, optimizing efficacy by focusing on biomarker subpopulations [36].

6 Vaccine Development for Virus-Induced Cancers

6.1 Current Vaccine Strategies and Effectiveness

Benchmark	Size	Domain	Task Format	Metric
Immunocto[13]	6,848,454	Histopathology	Cell Classification	F1 score
mIF/mIHC[2]	268	Pathology	Cell Segmentation	F1, IOU

Table 1: Table ef presents an overview of representative benchmarks used in the evaluation of immune cell interactions within histopathology and pathology domains. The table highlights the size of datasets, their respective domains, task formats, and the metrics employed for performance assessment, emphasizing the importance of these benchmarks in advancing vaccine efficacy strategies.

Advancements in vaccines targeting virus-induced cancers, notably Human Papillomavirus (HPV), have enhanced cancer prevention, significantly reducing cervical cancer incidence in regions like the Republic of Moldova [30]. These vaccines illustrate the proactive role of immunological strategies in combating viral oncogenesis. In lung cancer, therapeutic vaccines are emerging as part of broader immunotherapy, despite challenges in efficacy and patient-specific responses [62]. Pembrolizumab's integration with existing treatments in triple-negative breast cancer (TNBC) exemplifies vaccines' potential to boost antitumor immunity through innate and adaptive immune system synergy [12].

Understanding antibody-virus interactions is crucial for vaccine evaluation, as the sequence and positioning of antibody appearance significantly affect binding efficiency, with IgG showing the highest binding rates [19]. Insights from platforms like Immunocto, which provide extensive datasets on immune cell interactions, enhance strategies to improve vaccine efficacy [13]. To further comprehend the role of immune cell interactions in vaccine efficacy enhancement, Table 1 provides a detailed overview of representative benchmarks, illustrating the datasets and metrics pivotal to immunological research. Economic factors also play a pivotal role, with the immunotherapy market expected to grow substantially, highlighting the need for cost-effective vaccine strategies to alleviate the global burden of virus-induced cancers [16].

6.2 Innovative Approaches in Vaccine Development

Innovative strategies in vaccine development for virus-induced cancers focus on bolstering protection against oncogenic viruses. Trained immunity, involving long-term reprogramming of innate immune cells, enhances vaccine efficacy against oncogenic viruses [21]. Deep learning technologies, like DeepNovoV2, facilitate de novo peptide sequencing from mass spectrometry data, aiding in identifying novel viral antigens for vaccine targeting [46]. In high-risk populations, vaccines targeting specific viral antigens are crucial for cancer prevention, reducing incidence and strengthening prevention efforts [71].

Therapeutic approaches penetrating the blood-brain barrier offer new vaccine development opportunities, particularly for brain tumors linked to viral infections [35]. Advanced biomaterials and drug delivery systems, like nanoparticles, promise enhanced immune responses against oncogenic viruses with minimal adverse effects [23, 22]. Leveraging advancements in immunology, computational modeling, and targeted therapies paves the way for effective and personalized vaccine strategies to address virus-induced cancer challenges.

6.3 Predictive Biomarkers and Personalized Vaccines

Integrating predictive biomarkers into vaccine development enhances the personalization and efficacy of cancer immunotherapies. Biomarkers like microsatellite instability (MSI) and tumor mutational

burden (TMB) predict responses to immune checkpoint blockade (ICB) therapy, enabling tailored vaccine strategies [72]. The dual Cox model theory offers a framework for interpreting treatment responses, informing predictive biomarker development for personalized medicine [73]. Immunodominance shapes the virus-immune network, emphasizing the need to understand immune dynamics for effective vaccine development [48].

Predictive biomarkers influence vaccine administration timing and strategies. Research suggests timely vaccine administration post-surgery enhances immune responses, underscoring personalized strategies considering patient circumstances and treatment timelines [47]. Advanced peptide identification techniques, such as DeepNovoV2, improve antigen detection accuracy, critical for developing personalized cancer vaccines [46]. Future research should refine predictive models and explore additional biomarkers to enhance treatment personalization [74]. Incorporating biological correlates and validating models across diverse cell lines will improve predictive capabilities, leading to more effective personalized vaccine therapies [75].

7 Tumor Virology and Immune Response

7.1 Immune System Dynamics and Tumor Microenvironment

The complex interactions between the immune system and the tumor microenvironment (TME) in virus-induced cancers play a crucial role in determining cancer progression and treatment outcomes. The TME, consisting of various cell types, extracellular matrix elements, and signaling molecules, significantly influences immune responses, impacting the immune system's ability to detect and eliminate tumor cells. In the context of viral oncogenesis, the TME can either bolster or inhibit immune activity. Studies reveal that immune responses to viral therapies, such as oncolytic virotherapy, can sometimes reduce therapeutic effectiveness by promoting oscillatory dynamics between tumor and virus populations. Strategies aimed at reprogramming the immune microenvironment, such as enhancing $CD8^+$ T cell motility or limiting lymphocyte recruitment, could improve viral treatment efficacy by fostering a stronger immune response against tumors [26, 7, 27, 28].

Mathematical models offer valuable insights into these interactions, providing frameworks to simulate tumor growth and immune responses. For example, [76] demonstrate how cytokine-based periodic immunotherapy can modulate immune activity and control tumor progression, emphasizing the importance of timing and dosing in immunotherapeutic strategies. The hybrid discrete-continuum model by [67] elucidates the dynamics among uninfected and infected tumor cells, immune cells, and chemoattractants, offering a comprehensive analysis of spatial and temporal interactions within the TME. These models are crucial for understanding immune cell recruitment to tumor sites and their interactions with tumor cells and TME components.

The dynamics of viral escape and persistence, as discussed by [48], highlight the challenges the immune system faces in managing virus-induced tumors. Viral evasion of immune detection and persistent infections can lead to chronic inflammation and immune suppression, creating an environment conducive to tumor growth. Addressing these dynamics is essential for developing strategies that enhance immune surveillance and target viral components within the TME.

The interaction between the immune system and the TME is pivotal in the progression of virus-induced cancers and the efficacy of treatments, as the TME can hinder treatment delivery and effectiveness, including immunotherapies and nanomedicines, while promoting immunosuppression. Normalizing the TME may improve therapeutic outcomes by enhancing drug delivery and reducing immune suppression, potentially increasing the patient population benefiting from immunotherapy. Reprogramming the immune landscape within tumors could significantly boost oncolytic virotherapy effectiveness, suggesting the need for an integrated approach that combines TME modification with existing therapies [22, 7, 27, 28]. By integrating mathematical models and experimental data, researchers can deepen their understanding of these complex interactions and develop more effective strategies to modulate immune responses and improve patient outcomes in virus-associated malignancies.

7.2 Mechanisms of Immune Resistance

Virus-induced cancers often develop sophisticated mechanisms to evade immune responses, posing significant challenges to effective treatment. A key mechanism involves the adaptive immune

response, which, while crucial for targeting tumor cells, can inadvertently reduce the oncolytic activity of therapeutic viruses, thus decreasing their efficacy in tumor targeting [28].

The tumor microenvironment presents various physical and biological barriers that contribute to immune resistance. Inconsistent receptor expression on tumor cells can impede the binding and action of therapeutic agents, while immune cell-mediated clearance of viruses further limits the effectiveness of oncolytic virotherapy [27]. These barriers, along with the complex architecture of the TME, challenge immune cells' ability to infiltrate and eliminate tumor cells.

Innovative strategies are being explored to counteract these resistance mechanisms. Advanced modeling techniques, which consider the temporal dynamics of T-cell activation and infiltration, offer promising avenues for enhancing the therapeutic effects of combination treatments [75]. By optimizing the timing and coordination of immune responses, these models aim to improve immune cell penetration and efficacy within the TME.

Enhancing the infectivity and persistence of oncolytic viruses through genetic engineering and adjuvant incorporation may address immune barriers limiting therapeutic efficacy. However, mathematical modeling suggests that simply increasing viral infectivity might not guarantee complete tumor eradication, as it could lead to oscillations in tumor load that impede treatment effectiveness. Moreover, the TME presents significant challenges to both oncolytic virotherapy and immunotherapy by restricting drug delivery and fostering immunosuppression. Therefore, integrating advanced delivery technologies, such as nanoparticles, with immunotherapeutic approaches may enhance patient outcomes by normalizing the TME and improving the overall effectiveness of cancer therapies [23, 22, 27]. By modifying viral vectors to better evade immune detection and sustain oncolytic activity, researchers aim to enhance the overall effectiveness of virotherapy against immune resistance.

7.3 Innovative Therapeutic Strategies

Innovative therapeutic strategies in viral oncology and immunotherapy increasingly leverage insights into tumor virology and immune interactions to develop more effective treatments. A promising approach involves engineered oncolytic viruses designed to selectively target and destroy cancer cells while simultaneously stimulating an anti-tumor immune response [28]. These viruses can express specific antigens that enhance the immune system's ability to recognize and attack tumor cells, thereby overcoming limitations associated with traditional therapies.

The integration of mathematical and computational modeling has been pivotal in optimizing these therapeutic strategies. Hybrid discrete-continuum modeling approaches have been employed to simulate complex interactions among oncolytic viruses, tumor cells, and the immune system [67]. Such models provide valuable insights into the spatial and temporal dynamics of viral spread and immune cell infiltration within the TME, facilitating the design of more effective treatment protocols.

Combination therapies that integrate oncolytic virotherapy with modalities such as immune checkpoint inhibitors and CAR T-cell therapy represent another innovative strategy. These approaches aim to enhance overall treatment efficacy by targeting multiple pathways involved in tumor progression and immune evasion [25]. By addressing the intricate interplay between tumor cells and the immune system, these strategies hold potential to overcome resistance mechanisms and improve patient outcomes.

Furthermore, the development of personalized immunotherapies, guided by predictive biomarkers and advanced sequencing technologies, signifies a substantial advancement in cancer treatment. Tailoring therapeutic interventions to the unique genetic and immunological profiles of individual patients can enhance treatment precision and effectiveness, reducing adverse effects and improving overall survival rates [72].

8 Current Challenges and Future Directions

8.1 Challenges in Treatment Efficacy and Resistance

The quest for effective immunotherapy in virus-induced cancers is hindered by substantial challenges related to treatment efficacy and resistance. Single-agent therapies often yield low response rates, exacerbated by the immunosuppressive tumor microenvironment that curtails immune cell infiltration and activation, thereby impairing immunotherapeutic effectiveness [18]. This microenvironment fos-

ters both intrinsic and extrinsic resistance mechanisms, further complicated by tumor heterogeneity, which results in variable antigen presentation and immune evasion strategies. Such heterogeneity complicates predictive modeling, as current models frequently overlook spatial dynamics and fluctuations in immune cell activities [45].

Patient stratification is crucial, necessitating reliable biomarker identification to tailor therapies to individual profiles and enhance therapeutic outcomes. The limited efficacy of immunotherapies in solid tumors, coupled with unpredictable patient responses, underscores the urgency for improved biomarker validation to guide treatment decisions [23]. Additionally, slow and costly assessments of tumor-infiltrating lymphocytes (TILs) impede the clinical application of immunotherapies, affecting treatment planning and reproducibility [11].

The selective advantage of conservatively replicating viruses complicates treatment efficacy, as these viruses can evade immune detection and sustain infections. This necessitates careful consideration of antibody behavior and extensive empirical data to validate predictive models [5, 6]. Addressing these challenges requires a comprehensive strategy incorporating advanced mathematical modeling, enhanced molecular biomarker identification through deep learning applied to HE images, and innovative therapeutic strategies informed by multiplexed tissue imaging technologies. This approach aims to personalize treatments and improve patient outcomes [9, 77, 43].

8.2 Immunotherapy Side Effects and Safety Concerns

Immunotherapy in viral oncology, while promising, is accompanied by significant side effects and safety concerns. A primary challenge is balancing robust anti-tumor immune responses with the risk of excessive immune activation, which can lead to adverse effects. Regulatory T cells (Tregs) are vital for maintaining this balance; their dysregulation can result in immune-related adverse events (irAEs), posing significant challenges in immunotherapy [52].

Common irAEs include dermatological, gastrointestinal, hepatic, and endocrine disorders, stemming from immune attacks on healthy tissues. The unpredictability of irAEs, which vary widely in severity and timing among patients, complicates management and necessitates careful monitoring [36, 77]. Individual immune tumor microenvironment characteristics and specific biomarkers further influence these responses.

Cytokine release syndrome (CRS) represents a severe safety concern, resulting from heightened immune activation against cancer cells, leading to systemic inflammatory responses characterized by fever, fatigue, and organ dysfunction. Effective management strategies include preemptive measures such as corticosteroids or cytokine inhibitors [23, 44]. Tumor heterogeneity also contributes to safety concerns, as varying antigenic targets increase the risk of off-target effects and irAEs. Personalized treatment strategies informed by advanced imaging techniques and machine learning can enhance the analysis of unique tumor features, thereby improving targeted immunotherapy outcomes [40, 43].

8.3 Technological Advancements and Innovations

Viral oncology is advancing through the integration of emerging technologies and innovative methodologies that enhance the understanding and treatment of virus-induced cancers. A pivotal advancement is the application of nanomedicine, which improves drug delivery systems by enhancing the targeting and bioavailability of therapeutic agents, thereby increasing treatment precision and efficacy [23].

The introduction of kinetic Monte Carlo algorithms marks another breakthrough, facilitating sophisticated simulations of cancer-immune interactions. This technology allows researchers to model dynamic oscillations between immune and cancer cells, providing insights into immune responses and resistance mechanisms in viral oncology [17].

Mathematical modeling frameworks that combine individual-based and continuum approaches significantly contribute to the field, offering a comprehensive understanding of the coevolutionary dynamics between cytotoxic T lymphocytes (CTLs) and tumor cells, aiding in the prediction of treatment outcomes [78].

Innovative preclinical models are essential for bridging laboratory research with clinical applications, enabling the simulation of various treatment scenarios and the investigation of factors affecting treatment efficacy [8]. The integration of radiotherapy with immuno- and chemotherapy in mathe-

matical models allows for the exploration of synergistic effects, enhancing treatment planning and effectiveness [42, 79].

8.4 Personalized Medicine and Biomarker Development

The integration of personalized medicine and biomarker development is crucial for improving treatment outcomes in patients with virus-induced cancers. Personalized medicine aims to tailor therapeutic interventions based on the unique genetic and immunological profiles of patients, enhancing treatment precision and efficacy. Predictive biomarkers are essential for classifying patients into responders and non-responders, guiding personalized treatment strategies [18].

Advancing personalized medicine necessitates incorporating additional immune components into models and validating findings through larger studies. The potential for novel therapy combinations to enhance immune responses and mitigate resistance further emphasizes the need for personalized approaches [18].

Refining data augmentation techniques is vital for improving treatment outcomes by enhancing the predictive accuracy of response models. Given that approximately 15% of cancers globally are associated with viral infections, advanced computational methods, such as transformer-based architectures, are being developed to identify viral DNA in tumor samples effectively. These sophisticated strategies aim to optimize the analysis of complex tumor genomic data, ultimately leading to more effective and personalized immunotherapy approaches [22, 23, 39, 31, 80]. Future research should focus on refining models to include factors such as leukemic cell evolution and combination therapy effects, which are critical for personalized medicine and biomarker development.

Addressing the gaps in understanding the mechanisms of action for many immunotherapies and the need for personalized strategies based on individual patient profiles is essential. By integrating insights from oncolytic virotherapy, cancer immunotherapy, and nanomedicine, the development of personalized medicine and biomarkers can significantly enhance treatment outcomes for patients with virus-induced cancers. This multifaceted approach aims to optimize therapeutic efficacy while mitigating adverse effects, ultimately improving the quality of life for patients facing these complex malignancies [23, 39, 22, 7].

9 Conclusion

The survey underscores the pivotal role of immunotherapy, particularly immune checkpoint inhibitors, in revolutionizing cancer treatment, establishing their efficacy in managing advanced hepatocellular carcinoma (HCC) and enhancing patient survival rates. The integration of deep learning methodologies with conventional approaches is emphasized as a cornerstone for future cancer therapy advancements, advocating for a multidisciplinary framework. A proposed predictive model for bladder cancer immunotherapy outcomes demonstrates significant accuracy, highlighting its potential as a non-invasive diagnostic tool. Furthermore, the application of transformer models in predicting tumor volume changes illustrates the PULSAR effect's contribution to optimizing therapeutic results.

Understanding viral gene regulation emerges as a critical factor for therapeutic development, with a balanced immune response, especially involving cytotoxic T lymphocytes, being essential for effective vaccine creation against viral infections. Despite advancements in breast cancer immunotherapy, persistent challenges necessitate a comprehensive approach that synthesizes multiple therapeutic modalities. The personalized BCG treatment model notably enhances predictions of cancer cell dynamics, underscoring the importance of socio-demographic variables in treatment planning.

Future research directions include refining models to incorporate three-dimensional simulations and additional factors affecting antibody interactions, reinforcing the necessity of a multidisciplinary approach to enhance cancer treatment. The continuous influx of B-cells is crucial for maintaining CAR T-cell activation, potentially leading to tumor eradication and underscoring the need to understand immune system interactions in cancer therapy. Insights into the evolutionary advantages of conservative viral replication could pave the way for future cancer treatment innovations. Moreover, combining a ketogenic diet with immunotherapy presents promising potential for refining breast cancer treatment strategies.

Collectively, the findings highlight the indispensable role of a multidisciplinary approach in advancing cancer treatment through immunotherapy and viral oncology, offering substantial promise for future breakthroughs. The developed mathematical model effectively captures the PULSAR effect, aligning well with experimental data and providing insights into optimizing the synergy between radiotherapy and immunotherapy.

References

[1] Alireza Momenzadeh and Sima Sarv Ahrabi. Approximate analytical solution of a cancer immunotherapy model by the application of differential transform and adomian decomposition methods, 2018.

[2] Parmida Ghahremani, Joseph Marino, Juan Hernandez-Prera, Janis V. de la Iglesia, Robbert JC Slebos, Christine H. Chung, and Saad Nadeem. An ai-ready multiplex staining dataset for reproducible and accurate characterization of tumor immune microenvironment, 2023.

[3] Xuelin Wang, Yi Ren, and Jing Liu. Liquid metal enabled electrobiology: A generalized easy going way to tackle disease challenges, 2018.

[4] Pedro Berraondo, Miguel F Sanmamed, María C Ochoa, Iñaki Etxeberria, Maria A Aznar, José Luis Pérez-Gracia, María E Rodríguez-Ruiz, Mariano Ponz-Sarvise, Eduardo Castañón, and Ignacio Melero. Cytokines in clinical cancer immunotherapy. *British journal of cancer*, 120(1):6–15, 2019.

[5] Yisroel Brumer and Eugene I. Shakhnovich. A selective advantage for conservative viruses, 2004.

[6] Charlotte Dugourd-Camus, Claudia P. Ferreira, and Mostafa Adimy. Modeling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections, 2024.

[7] Narges Ramezani and Erfan Mohammadi. The role of public health in the fight against cancer: Awareness, prevention, and early detection, 2023.

[8] Timothy A Yap, Eileen E Parkes, Weiyi Peng, Justin T Moyers, Michael A Curran, and Hussein A Tawbi. Development of immunotherapy combination strategies in cancer. *Cancer discovery*, 11(6):1368–1397, 2021.

[9] Anna Konstorum, Anthony T. Vella, Adam J. Adler, and Reinhard Laubenbacher. Addressing current challenges in cancer immunotherapy with mathematical and computational modeling, 2017.

[10] Claudia Cecchetto, Marta Maschietto, Pasquale Boccaccio, and Stefano Vassanelli. Enhancement of kv1.3 potassium conductance by extremely low frequency electromagnetic field, 2015.

[11] Amine Marzouki, Zhuxian Guo, Qinghe Zeng, Camille Kurtz, and Nicolas Loménie. Optimizing lymphocyte detection in breast cancer whole slide imaging through data-centric strategies, 2024.

[12] Grace Sun and Sandip Patel. Exploring the contribution of innate immune cells to breast cancer immunotherapy, 2023.

[13] Mikaël Simard, Zhuoyan Shen, Konstantin Bräutigam, Rasha Abu-Eid, Maria A. Hawkins, and Charles-Antoine Collins-Fekete. Immunocto: a massive immune cell database auto-generated for histopathology, 2025.

[14] Hassnaa Akil and Nadia Idrissi Fatmi. A mathematical model of breast cancer (er+) with excess estrogen: Mixed treatments using ketogenic diet, endocrine therapy and immunotherapy, 2022.

[15] Shagufta Henna. Understanding human innate immune system dependencies using graph neural networks, 2021.

[16] Matthew J Buettner, Sagar R Shah, Christopher T Saeui, Ryan Ariss, and Kevin J Yarema. Improving immunotherapy through glycodesign. *Frontiers in immunology*, 9:2485, 2018.

[17] Léon Masurel, Carlo Bianca, and Annie Lemarchand. Oscillations of the number of immune system cells in a space-velocity thermostatted kinetic theory model of tumor growth, 2021.

[18] Leisha A Emens. Breast cancer immunotherapy: facts and hopes. *Clinical cancer research*, 24(3):511–520, 2018.

[19] Luman Haris, Sony Suhandono, Siti Nurul Khotimah, Freddy Haryanto, and Sparisoma Viridi. Study on antibody-virus interaction using molecular dynamics: Two dimensional simulation on immunoglobulin reaction against human papillomavirus, 2013.

[20] Yang Shi and Twan Lammers. Combining nanomedicine and immunotherapy. *Accounts of chemical research*, 52(6):1543–1554, 2019.

[21] Jezabel Varadé, Susana Magadán, and África González-Fernández. Human immunology and immunotherapy: main achievements and challenges. *Cellular & molecular immunology*, 18(4):805–828, 2021.

[22] John D Martin, Horacio Cabral, Triantafyllos Stylianopoulos, and Rakesh K Jain. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. *Nature reviews Clinical oncology*, 17(4):251–266, 2020.

[23] Rachel S Riley, Carl H June, Robert Langer, and Michael J Mitchell. Delivery technologies for cancer immunotherapy. *Nature reviews Drug discovery*, 18(3):175–196, 2019.

[24] Darrell J Irvine and Eric L Dane. Enhancing cancer immunotherapy with nanomedicine. *Nature Reviews Immunology*, 20(5):321–334, 2020.

[25] Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, and Chong-xian Pan. Combination strategies to maximize the benefits of cancer immunotherapy. *Journal of hematology & oncology*, 14(1):156, 2021.

[26] S. C. Ferreira Jr. au2, M. L. Martins, and M. J. Vilela. Fighting cancer with virus, 2003.

[27] Pantea Pooladvand, Chae-Ok Yun, A-Rum Yoon, Peter S. Kim, and Federico Frascoli. The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study, 2021.

[28] Leticia R Paiva, Hallan S Silva, Silvio C Ferreira, and Marcelo L Martins. Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer, 2013.

[29] Maria Werner, LiZhe Zhu, and Erik Aurell. Cooperative action in eukaryotic gene regulation: physical properties of a viral example, 2007.

[30] Andrzej Jarynowski. Hpv and cervical cancer in moldova, epidemiological model with intervention cost vs benefit and effectiveness analysis, 2015.

[31] Shorya Consul, John Robertson, and Haris Vikalo. Xvir: A transformer-based architecture for identifying viral reads from cancer samples, 2023.

[32] Jie Ren, Kai Song, Chao Deng, Nathan A. Ahlgren, Jed A. Fuhrman, Yi Li, Xiaohui Xie, and Fengzhu Sun. Identifying viruses from metagenomic data by deep learning, 2018.

[33] Artem S. Novozhilov, Faina S. Berezovskaya, Eugene V. Koonin, and Georgy P. Karev. Mathematical modeling of anti-tumor virus therapy: Regimes with complete recovery within the framework of deterministic models, 2005.

[34] Thi Ngan Dong, Graham Brogden, Gisa Gerold, and Megha Khosla. A multitask transfer learning framework for the prediction of virus-human protein-protein interactions, 2021.

[35] Sandip Banerjee, Subhas Khajanchi, and Swapna Chowdhury. Mathematical modeling to elucidate brain tumor abrogation by immunotherapy with t11 target structure, 2015.

[36] Anh Nguyen Duc, Dominik Heinzmann, Claude Berge, and Marcel Wolbers. A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies, 2020.

[37] Bernardo Flores and Peter Mueller. Clustering and meta-analysis using a mixture of dependent linear tail-free priors, 2024.

[38] C Lee Ventola. Cancer immunotherapy, part 3: challenges and future trends. *Pharmacy and Therapeutics*, 42(8):514, 2017.

[39] Joseph Malinzi, Rachid Ouifki, Amina Eladdadi, Delfim F. M. Torres, and K. A. Jane White. Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis, 2018.

[40] Jonatan A. González, Julia Wrobel, Simon Vandekar, and Paula Moraga. Analysing spatial point patterns in digital pathology: immune cells in high-grade serous ovarian carcinomas, 2023.

[41] Bruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, and Ignacio Melero. Advances in immunotherapy for hepatocellular carcinoma. *Nature reviews Gastroenterology & hepatology*, 18(8):525–543, 2021.

[42] Jayanth Pratap. An optimal control strategy for mathematically modeling cancer combination therapy, 2021.

[43] Heather D. Couture. Deep learning-based prediction of molecular tumor biomarkers from he: A practical review, 2022.

[44] Virginia Bayer, Beau Amaya, Diane Baniewicz, Colleen Callahan, Lisa Marsh, and Asia S McCoy. Cancer immunotherapy. *Clinical journal of oncology nursing*, 21(2), 2017.

[45] Emma Leschiera, Tommaso Lorenzi, Shensi Shen, Luis Almeida, and Chloe Audebert. A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour cd8+ t cell immune response, 2021.

[46] Rui Qiao, Ngoc Hieu Tran, Lei Xin, Baozhen Shan, Ming Li, and Ali Ghodsi. Deepnovov2: Better de novo peptide sequencing with deep learning, 2019.

[47] O. G. Isaeva and V. A. Osipov. Different strategies for cancer treatment: Mathematical modeling, 2008.

[48] Cameron J. Browne and Hal L. Smith. Dynamics of virus and immune response in multi-epitope network, 2018.

[49] Clare C. Yu, Juliana C. Wortman, Ting-Fang He, Shawn Solomon, Robert Z. Zhang, Anthony Rosario, Roger Wang, Travis Y. Tu, Daniel Schmolze, Yuan Yuan, Susan E. Yost, Xuefei Li, Herbert Levine, Gurinder Atwal, and Peter P. Lee. Physics approaches to the spatial distribution of immune cells in tumors, 2019.

[50] Mikhail V Pogorelyy, Anastasia A Minervina, Mikhail Shugay, Dmitriy M Chudakov, Yuri B Lebedev, Thierry Mora, and Aleksandra M Walczak. Detecting t-cell receptors involved in immune responses from single repertoire snapshots, 2018.

[51] Thierry Gobron, Mario Santoro, and Livio Triolo. Competing hiv strains and immune system response, 2011.

[52] Tamás Szabados, Csaba Kerepesi, and Tibor Bakács. Mistimm: a simulation tool to compare classical nonsef-centered immune models with a novel self-centered model, 2018.

[53] Prajwal Ghimire, Ben Kinnersley, Golestan Karami, Prabhu Arumugam, Richard Houlston, Keyoumars Ashkan, Marc Modat, and Thomas C Booth. Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies, 2024.

[54] Thomas Beneteau, Christian Selinger, Mircea T. Sofonea, and Samuel Alizon. Episome partitioning and symmetric cell divisions: quantifying the role of random events in the persistence of hpv infections, 2021.

[55] Soumya Banerjee. Optimal strategies for virus propagation, 2016.

[56] Nikita Vladimirov and Or Perlman. Molecular mri-based monitoring of cancer immunotherapy treatment response, 2023.

[57] Abdulhamed Alsisi, Raluca Eftimie, and Dumitru Trucu. Nonlocal multiscale modelling of tumour-oncolytic viruses interactions within a heterogeneous fibrous/non-fibrous extracellular matrix, 2021.

[58] Yifan Wu and Yousong Peng. Ten computational challenges in human virome studies, 2024.

[59] Zineb Kaid, Camille Pouchol, and Jean Clairambault. A phenotype-structured model for the tumour-immune response, 2023.

[60] Odelaisy Leon-Triana, Soukaina Sabir, Gabriel F. Calvo, Juan Belmonte-Beitia, Salvador Chulian, Alvaro Martinez-Rubio, Maria Rosa, Antonio Perez-Martinez, Manuel Ramirez Orellana, and Victor M. Perez-Garcia. Car t cell therapy in b-cell acute lymphoblastic leukaemia: Insights from mathematical models, 2020.

[61] Stephan Kruger, Matthias Ilmer, Sebastian Kobold, Bruno L Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W Renz, Jan G D'Haese, Hans Schloesser, et al. Advances in cancer immunotherapy 2019–latest trends. *Journal of Experimental & Clinical Cancer Research*, 38:1–11, 2019.

[62] Aritraa Lahiri, Avik Maji, Pravin D Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee, and Manash K Paul. Lung cancer immunotherapy: progress, pitfalls, and promises. *Molecular cancer*, 22(1):40, 2023.

[63] Ujwani Nukala, Marisabel Rodriguez Messan, Osman N. Yogurtcu, Xiaofei Wang, and Hong Yang. A systematic review of the efforts and hindrances of modeling and simulation of car t-cell therapy, 2021.

[64] Sergio Serrano, Roberto Barrio, Álvaro Martínez-Rubio, Juan Belmonte-Beitia, and Víctor M. Pérez-García. Understanding the role of b-cells in car t-cell therapy in leukemia through a mathematical model, 2024.

[65] Zizi Wang. Modeling oncolytic virus therapy with distributed delay and non-local diffusion, 2024.

[66] Thomas Williams, James McCaw, and James Osborne. Choice of spatial discretisation influences the progression of viral infection within multicellular tissues, 2022.

[67] David Morselli, Marcello E. Delitala, Adrianne L. Jenner, and Federico Frascoli. A hybrid discrete-continuum modelling approach for the interactions of the immune system with oncolytic viral infections, 2024.

[68] J. C. Phillips. Punctuated evolution of influenza virus hemagglutinin (a/h1n1) under opposing migration and vaccination pressures, 2012.

[69] Heyrim Cho, Zuping Wang, and Doron Levy. Study of dose-dependent combination immunotherapy using engineered t cells and il-2 in cervical cancer, 2020.

[70] Thomas A Waldmann. Cytokines in cancer immunotherapy. *Cold Spring Harbor perspectives in biology*, 10(12):a028472, 2018.

[71] Robert H Vonderheide, Susan M Domchek, and Amy S Clark. Immunotherapy for breast cancer: what are we missing? *Clinical Cancer Research*, 23(11):2640–2646, 2017.

[72] Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang, and Xinxiang Li. Exploring immunotherapy in colorectal cancer. *Journal of hematology & oncology*, 15(1):95, 2022.

[73] Powei Chen, Siying Hu, and Haojin Zhou. A dual cox model theory and its applications in oncology, 2023.

[74] Souvik Roy and Suvra Pal. Optimal personalized therapies in colon-cancer induced immune response using a fokker-planck framework, 2022.

[75] Samiha Rouf, Casey Moore, Debabrata Saha, Dan Nguyen, MaryLena Bleile, Robert Timmerman, Hao Peng, and Steve Jiang. Pulsar effect: Revealing potential synergies in combined radiation therapy and immunotherapy via differential equations, 2024.

[76] D. Rodriguez-Perez, Oscar Sotolongo-Grau, Ramon Espinosa Riquelme, Oscar Sotolongo-Costa, J. Antonio Santos Miranda, and J. C. Antoranz. Tumors under periodic therapy – role of the immune response time delay, 2006.

[77] Martin Paulikat, Christian M. Schürch, and Christian F. Baumgartner. Studying therapy effects and disease outcomes in silico using artificial counterfactual tissue samples, 2023.

[78] Luís Almeida, Chloe Audebert, Emma Leschiera, and Tommaso Lorenzi. Discrete and continuum models for the coevolutionary dynamics between cd8+ cytotoxic t lymphocytes and tumour cells, 2022.

[79] Yixun Xing, Casey Moore, Debabrata Saha, Dan Nguyen, MaryLena Bleile, Xun Jia, Robert Timmerman, Hao Peng, and Steve Jiang. Mathematical modeling of the synergetic effect between radiotherapy and immunotherapy, 2023.

[80] Francesco Rundo, Concetto Spampinato, and Michael Rundo. Non-linear self augmentation deep pipeline for cancer treatment outcome prediction, 2023.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.